Page 5 - Hernan Levett News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances demonstrating potent in vitro and in vivo antimicrobial activity against MDR and XDR Enterobacteriaceae, including carbapenem-resistant and colistin-resistant strains
forextv.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forextv.com Daily Mail and Mail on Sunday newspapers.

United statesSwitzerland generalUnited kingdomHernan levettOliver zerbeStephan feldhausEuropean centre for disease preventionCenters for diseaseWorld health organizationUniversity of zurichProfessor oliver zerbeAntibiotics disruptLipopolysaccharide transport bridgeDrug resistant enterobacteriaceaeScience advancesDisease control

Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances

Spexis AG / Key word: Scientific publication Spexis announces the publication of promising results for a novel class of macrocyclic, peptidomimetic antibiotics in Science Advances. | June 7, 2023

United statesSwitzerland generalUnited kingdomOliver zerbeStephan feldhausHernan levettEuropean centre for disease preventionWorld health organizationUniversity of zurichCenters for diseaseScience advancesProfessor oliver zerbeAntibiotics disruptLipopolysaccharide transport bridgeDrug resistant enterobacteriaceaeDisease control

Spexis provides business update and announces financial results for the full year 2022

Spexis AG / Key word: Annual Results/Annual Results Spexis provides business update and announces financial results for the full year 2022 30-May-2023 / 07:15 CET/CEST Release of an ad hoc. | May 30, 2023

United statesSwitzerland generalStephan feldhausHernan levettUnited states food drug administrationJeff wagerUnited states foodDrug administrationDrug designationQualified infectious disease productFast trackSpexis ag stock exchangePress releaseD poln ch0106213793

Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®

Spexis AG / Key word(s): Financing/Partnership Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund.

United statesSwitzerland generalBrigitte keller laurie doyleStephen jasperDaniel martinezHernan levettStephan feldhausThomas fratacciRaimund gabrielMc servicesGilmartin groupUnited states food drug administrationClinical development costs of colifinClinical trial partnership to fundAnnounce plansClinical trial partnership

Spexis reports solid safety and pharmacokinetics results

Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’.

Switzerland generalHernan levettStephan feldhausJuergen froehlichEuropean innovative medicines initiativeChief medical officerSwiss stock exchange spex swPexis agCystic fibrosisOn cf bronchiectasisClinical dataPhase 1